NCT05393557View on ClinicalTrials.gov

Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction

NANot yet recruitingINTERVENTIONAL
Enrollment

626

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions
STEMILarge Thrombus BurdenNo-Reflow Phenomenon
Interventions
OTHER

Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury

Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation

All Listed Sponsors
collaborator

Aswan Heart Centre

OTHER

lead

Cairo University

OTHER

NCT05393557 - Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction | Biotech Hunter | Biotech Hunter